TOMI Environmental Solutions Receives Biocidal Product Approvals in Great Britain and Northern Ireland
Rhea-AI Summary
TOMI Environmental Solutions (NASDAQ: TOMZ) received Health and Safety Executive authorizations GB-2016-1042 (Great Britain) and NI-2026-1350 (Northern Ireland) on Feb. 23, 2026, allowing its Binary Ionization Technology (BIT) and SteraMist iHP products for registered biocidal uses.
Approvals cover room fogging and handheld surface spray on dry, pre-cleaned, hard, non-porous surfaces across healthcare, industrial, hospitality, and institutional sectors; specific EN and AOAC efficacy contact times are listed for bactericidal, yeasticidal, and virucidal claims.
Positive
- Official HSE authorizations: GB-2016-1042 and NI-2026-1350
- Approved for room fogging and handheld spray surface applications
- Efficacy claims include EN 13727, EN 13624, EN 14476 with 5–15 minute contact times
Negative
- Use limited to dry, pre-cleaned, hard, non-porous, non-food contact surfaces
- EU market access remains pending—EU BPR approval is not yet granted
Key Figures
Market Reality Check
Peers on Argus
TOMZ shows a modest pre-news gain of 0.13% with very light volume, while peers are mixed: LIQT +2.67%, ZONE +4.27%, DEVS +25.3%, CLIR -4.59%, and CLWT flat. Movements do not indicate a coordinated sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 20 | UK CES integration | Positive | +0.6% | Sale of SteraMist CES into UK modular cleanroom platform for pharma use. |
| Jan 06 | Hybrid system sale | Positive | -3.0% | SteraMist Hybrid System installed at research university sterilization facility. |
| Dec 22 | Cell/gene facility win | Positive | +2.2% | Multi-stage SteraMist iHP rollout at commercial cell and gene therapy site. |
| Dec 18 | Biopharma PO $500k | Positive | -0.1% | Approx. $500,000 SteraMist integration order from global biopharma leader. |
| Dec 15 | Cruise line outreach | Positive | -5.1% | Call for cruise lines to adopt hospital-grade SteraMist decontamination tech. |
Positive commercial/strategic news has produced mixed reactions, with more instances of divergence than alignment between fundamentally positive headlines and next-day price moves.
Over the last few months, TOMI has reported a series of SteraMist deployments and commercial wins, including a $500,000 purchase order with a global biopharma leader on Dec 18, 2025 and multi-stage implementation at a cell and gene therapy facility on Dec 22, 2025. Additional installations at a research university and a UK CES integration further expanded use cases. Despite generally positive operational updates, 24-hour price reactions have been inconsistent, sometimes negative even on constructive news. Today’s UK and Northern Ireland biocidal approvals extend that regulatory/commercial trajectory.
Regulatory & Risk Context
On Nov 14, 2025, TOMI filed an S-3 shelf registration to offer up to $50,000,000 in various securities. The shelf is noted as not yet effective and has 0 recorded usage in the context data, but, once effective and used, could facilitate capital raises that may affect existing shareholders.
Market Pulse Summary
This announcement secures biocidal product approvals for TOMI’s BIT solution and SteraMist equipment in both Great Britain and Northern Ireland, broadening potential use across healthcare, industrial, and institutional settings. It extends a series of recent SteraMist wins in pharmaceutical and research environments. At the same time, TOMI faces Nasdaq compliance issues and maintains an unused $50,000,000 S-3 shelf. Investors may watch how quickly these new regulatory clearances translate into contracts and revenue traction.
Key Terms
binary ionization technology technical
ionized hydrogen peroxide medical
AI-generated analysis. Not financial advice.
Health and Safety Executive (HSE) grants Authorization Nos.: GB-2016-1042 and NI-2026-1350
FREDERICK, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced that Health and Safety Executive (HSE), Great Britian’s national regulator for health and safety, has granted official authorization for its Binary Ionization Technology (BIT) solution and the SteraMist iHP brand of disinfection equipment. The BIT Solution is now formally approved as a biocidal product for use in Great Britain, which includes England, Scotland, and Wales under Regulation 528/2012 GB. A separate approval was also received for Northern Ireland under Regulation (EU) No. 528/2012.
This milestone marks a significant achievement for TOMI, as it paves the way for expanding the availability of BIT and SteraMist products in both Great Britain and Northern Ireland. The BIT solution is approved under Regulation 528/2012 for room fogging and handheld direct spray applications. It is intended for use as a microbial disinfectant on surfaces, walls, floors, furniture, and rooms across various sectors, including healthcare, industrial, commercial, hospitality, and institutional settings.
Elissa J. Shane, COO of TOMI, stated, “This not only enhances our market footprint but also reinforces our commitment to providing innovative solutions that meet rigorous compliance, safety, and efficacy standards. We are optimistic that our separate application under the EU Biocidal Products Regulation (BPR) for the European Union will also be approved this year, opening doors in additional countries across Europe.”
The BIT solution is designed for disinfection of all dry, pre-cleaned, hard, non-porous, non-food contact surfaces in spaces such as pharmaceutical manufacturing clean rooms, tissue labs, laboratories, animal research facilities, hotel rooms, cruise ships, and recreational facilities.
The following efficacy claims have been established for TOMI's BIT solution in Great Britain:
| STANDARD | CONTACT TIME | STANDARD | CONTACT TIME | STANDARD | CONTACT TIME |
| Bactericidal | Yeasticidal | Virucidal | |||
| SURFACE APPLICATION | |||||
| EN 13727 | 5 min. | EN 13624 | 5 min. | EN 14476 | 5 min. |
| AOAC Germicidal Spray Method; NF-T 72-281; EN 13697 | 7 min. | NF T 72-281; EN 13697 | 7 min. | AOAC Germicidal Spray Method; NF T 72-281: | 7 min. |
| ROOM FOGGING | |||||
| EN 13727 | 5 min | EN 13624 | 5 min | EN 14476 | 5 min |
| NF T 72-281 EN 13697; AOAC Germicidal Fog Method | 15 min. | NF T 72-281; EN 13697 | 15 min. | NF T 72-28; AOAC Germicidal Spray Method | 15 min. |
TOMI’s SteraMist products utilize a low percentage of Hydrogen Peroxide as the only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™), which creates a germ-killing aerosol that functions like a non-caustic gas. These products are designed for a wide range of applications, including hospitals, medical facilities, schools, restaurants, military barracks, and more.
About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.
For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services serving the food safety sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
FAQ
What approvals did TOMI (TOMZ) receive in Great Britain and Northern Ireland on Feb. 23, 2026?
What applications are authorized for TOMI's BIT solution under the HSE approvals?
Which efficacy standards and contact times does TOMI's BIT claim in Great Britain?
Does the HSE authorization allow TOMI to sell SteraMist iHP across all surface types?
What geographic expansion does the HSE approval enable for TOMI (TOMZ)?
Has TOMI received EU-wide approval for BIT under the Biocidal Products Regulation (BPR)?
